Ignite Creation Date:
2024-05-05 @ 11:58 PM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01468441
Status:
COMPLETED
Last Update Posted:
2012-07-13
First Post:
2011-10-31
Brief Title:
Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone FSH and Gonadotrophin Releasing Hormone GnRH Agonist in Alternate Days
Sponsor:
Fertility - Assisted Fertilization Center
Organization:
Fertility - Assisted Fertilization Center
Study Overview
Official Title:
Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Gonapeptyl
Brief Summary:
The present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone GnRH antagonist vs an alternate-day dosage of GnRH agonist on ovarian response and in vitro fertilization IVF outcome in patients stimulated with recombinant follicle-stimulating hormone FSH and human chorionic gonadotrophin hCG microdose
Detailed Description:
Inclusion criteria were as follows women of good physical and mental health under 37 years old with regular menstrual cycles of 25-35 days normal basal FSH and luteinizing hormone LH levels body mass index BMI less than 30 kgm2 presence of both ovaries and intact uterus absence of polycystic ovaries endometriosis or gynaecological medical disorders and a negative result in a screening for sexually transmitted diseases
No patient had received any hormone therapy for at least 60 days preceding the study Eligible patients who agreed to participate were randomized in two treatment groups Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table
No patient had received any hormone therapy for at least 60 days preceding the study Eligible patients who agreed to participate were randomized in two treatment groups Patients were allocated to a GnRH analogue treatment group according to a computer-generated randomization table
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None